dc.date.accessioned2019-02-06T14:51:20Z
dc.date.available2019-02-06T14:51:20Z
dc.date.created2019-02-06T14:51:20Z
dc.date.issued2016
dc.identifierhttps://hdl.handle.net/20.500.12866/5220
dc.identifierhttps://doi.org/10.1038/ng.3588
dc.description.abstractPlasmodium vivax is a major public health burden, responsible for the majority of malaria infections outside Africa. We explored the impact of demographic history and selective pressures on the P. vivax genome by sequencing 182 clinical isolates sampled from 11 countries across the globe, using hybrid selection to overcome human DNA contamination. We confirmed previous reports of high genomic diversity in P. vivax relative to the more virulent Plasmodium falciparum species; regional populations of P. vivax exhibited greater diversity than the global P. falciparum population, indicating a large and/or stable population. Signals of natural selection suggest that P. vivax is evolving in response to antimalarial drugs and is adapting to regional differences in the human host and the mosquito vector. These findings underline the variable epidemiology of this parasite species and highlight the breadth of approaches that may be required to eliminate P. vivax globally.
dc.languageeng
dc.publisherSpringer Nature
dc.relationNature Genetics
dc.relation1546-1718
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAntimalarials/pharmacology
dc.subjectDrug Resistance/genetics
dc.subjectGenetic Markers/genetics
dc.subjectHumans
dc.subjectMalaria, Vivax/drug therapy/genetics/parasitology
dc.subjectMetagenomics/methods
dc.subjectPlasmodium vivax/drug effects/genetics/pathogenicity
dc.subjectSelection, Genetic/drug effects/genetics
dc.subjectTranscriptome/genetics
dc.titlePopulation genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución